Repligen Announces Agreement to Acquire Chromatography Innovator Tantti

• Proposed acquisition adds novel macroporous chromatography base bead technology for downstream bioprocess applications
  
• Accelerates expansion into new modality markets with a unique, scalable purification solution
• Strongly synergistic with AVIPure affinity ligands and OPUS pre-packed chromatography columns
  

WALTHAM, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held Tantti Laboratory Inc. (“Tantti”) of Taoyuan City, Taiwan. Tantti has developed a unique portfolio of macroporous chromatography beads to optimize the purification of new modalities including viral vectors, viruses, nucleic acids and other large molecule biologics.

Tantti’s DuloCore technology platform combines the high throughput performance of membranes with the rapid mass transfer of monoliths in a convenient and flexible bead format. Combined with AVIPure affinity ligands, the technology will provide additional performance advantages such as molecule selectivity, and increased efficiencies to address downstream bottleneck challenges and scalability concerns of manufacturers. The resins can be pre-packed for customers into Repligen’s OPUS Columns, where the company offers the industry’s widest range of sizes for scalability and efficiency.

Tony J. Hunt, Chief Executive Officer at Repligen said, “The addition of Tantti further strengthens our portfolio in the new modality space. Combining Tantti’s innovative bead technology with the content we are generating from Avitide will be game-changing. The industry needs high throughput and high-capacity purification products, and Tantti is the solution to delivering on this. We are excited to welcome the Tantti team to Repligen, and we look forward to further developing and integrating their differentiated technology into our portfolio.”

Joe Yang, Chief Executive Officer at Tantti said, “We have been working with Repligen for a few years now and we are thrilled to combine the power of Tantti’s bead technology with the capabilities of Avitide and to leverage the commercial strength of Repligen to make DuloCore the gold-standard in the marketplace for new modality purification. Repligen is the ideal partner for us to take this next step of growth and we look forward to working with our colleagues at Repligen to accelerate our market presence in bioprocessing.”